Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EPS (Basic): 2013-2024

Historic EPS (Basic) for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $0.38.

  • CytomX Therapeutics' EPS (Basic) fell 228.57% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.41, marking a year-over-year increase of 140.05%. This contributed to the annual value of $0.38 for FY2024, which is 3900.00% up from last year.
  • Per CytomX Therapeutics' latest filing, its EPS (Basic) stood at $0.38 for FY2024, which was up 3,900.00% from -$0.01 recorded in FY2023.
  • In the past 5 years, CytomX Therapeutics' EPS (Basic) ranged from a high of $0.38 in FY2024 and a low of -$1.81 during FY2021.
  • Over the past 3 years, CytomX Therapeutics' median EPS (Basic) value was -$0.01 (recorded in 2023), while the average stood at -$0.38.
  • Per our database at Business Quant, CytomX Therapeutics' EPS (Basic) dropped by 29.29% in 2021 and then surged by 3,900.00% in 2024.
  • Over the past 5 years, CytomX Therapeutics' EPS (Basic) (Yearly) stood at -$1.40 in 2020, then declined by 29.29% to -$1.81 in 2021, then rose by 16.57% to -$1.51 in 2022, then soared by 99.34% to -$0.01 in 2023, then soared by 3,900.00% to $0.38 in 2024.